ACAD - CIK 0001070494
ACADIA PHARMACEUTICALS INC (ACAD) reported net income of $391.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $391.00M | +73.0% |
| FY 2024 | $226.00M | +470.5% |
| FY 2023 | -$61.00M | +71.5% |
| FY 2022 | -$214.00M | -27.4% |
| FY 2021 | -$168.00M | +40.3% |
| FY 2020 | -$281.58M | -19.7% |
| FY 2019 | -$235.26M | +4.1% |
| FY 2018 | -$245.19M | +15.3% |
| FY 2017 |
ACADIA PHARMACEUTICALS INC (ACAD) reported net income of $391.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ACADIA PHARMACEUTICALS INC's net income grew from -$22.77M to $391.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$289.40M |
| -6.6% |
| FY 2016 | -$271.39M | -65.0% |
| FY 2015 | -$164.44M | -77.8% |
| FY 2014 | -$92.47M | -143.7% |
| FY 2013 | -$37.95M | -82.0% |
| FY 2012 | -$20.85M | +8.4% |
| FY 2011 | -$22.77M | - |